Vor Biopharma (VOR) Research & Development (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Research & Development of $17.6 million for Q1 2026, down 34.1% year-over-year from $26.7 million in Q1 2025, and down 8.31% quarter-over-quarter from $19.2 million in Q4 2025.
Vor Biopharma (VOR) Research & Development (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Research & Development for 7 consecutive years, with $17.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 34.1% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $312.4 million (up 226.5% YoY), while the FY2025 annual figure was $321.5 million, up 244.58% from the prior year.
- Research & Development retreated to $17.6 million in Q1 2026 per VOR's latest filing, from $19.2 million in the prior quarter.
- Across five years, Research & Development topped out at $261.5 million in Q2 2025 and bottomed at $14.1 million in Q3 2025.
- Historically, Research & Development has averaged $34.8 million across 5 years, with a median of $21.8 million in 2024.
- On a YoY basis, Research & Development climbed as much as 1098.27% in 2025 and fell as far as 35.18% in 2025.
- Vor Biopharma's Research & Development stood at $17.1 million in 2022, then increased by 22.48% to $20.9 million in 2023, then advanced by 21.3% to $25.3 million in 2024, then decreased by 24.29% to $19.2 million in 2025, then retreated by 8.31% to $17.6 million in 2026.
- Business Quant data shows VOR's Research & Development at $17.6 million in Q1 2026, $19.2 million in Q4 2025, and $14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 25.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.92 Mn |
| Mar 31, 2026 | 17.60 Mn |
| Dec 31, 2025 | 19.19 Mn |
| Sep 30, 2025 | 14.14 Mn |
| Jun 30, 2025 | 261.50 Mn |
| Mar 31, 2025 | 26.70 Mn |
| Dec 31, 2024 | 25.35 Mn |
| Sep 30, 2024 | 21.82 Mn |
| Jun 30, 2024 | 21.82 Mn |
| Mar 31, 2024 | 24.32 Mn |
| Dec 31, 2023 | 20.90 Mn |
| Sep 30, 2023 | 27.61 Mn |
| Jun 30, 2023 | 23.90 Mn |
| Mar 31, 2023 | 21.92 Mn |
| Dec 31, 2022 | 17.06 Mn |
| Sep 30, 2022 | 16.88 Mn |
| Jun 30, 2022 | 15.33 Mn |
| Mar 31, 2022 | 15.28 Mn |
| Dec 31, 2021 | 12.69 Mn |
| Sep 30, 2021 | 12.93 Mn |